Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma

This indirect comparison of dupilumab, mepolizumab and omalizumab for patients with severe type 2 asthma fulfilling start-up criteria for more than one drug shows no significant efficacy differences https://bit.ly/3pK9Nf9

Detalles Bibliográficos
Autores principales: Prætorius, Katrine, Henriksen, Daniel P., Schmid, Johannes M., Printzlau, Pernille, Pedersen, Lars, Madsen, Hanne, Andersson, Ehm A., Madsen, Louise Klokker, Chawes, Bo L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405862/
https://www.ncbi.nlm.nih.gov/pubmed/34476242
http://dx.doi.org/10.1183/23120541.00306-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405862/
https://www.ncbi.nlm.nih.gov/pubmed/34476242
http://dx.doi.org/10.1183/23120541.00306-2021

Ejemplares similares